Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib in Chinese Patients With B-cell Lymphoma
NCT03189524Phase 1Completed
- Sponsor
- BeiGene
- Start
- Jul 2016
- Primary completion
- Aug 2020
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 1, open-label trial of zanubrutinib in B cell lymphoma, follicular lymphoma (FL) and marginal zone lymphoma (MZL) (3 arms), sponsored by BeiGene. Primary endpoints: Treatment-emergent Adverse Events and Serious Adverse Events, Overall Response Rate and 4 more. Started Jul 2016; status: completed.
02
Drugs
zanubrutinib
03
Conditions
B cell lymphomafollicular lymphoma (FL)marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT03189524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03189524.